Assessment of PD-L1 expression in patients with urothelial cancer with contraindications to platinum based therapy

Background. Urothelial cancer ranks 7th and 17th of all the malignant tumors in males and females, respectively. Development of new immunotherapeutic drugs provides new possibilities in treatment of such patients, especially the patient population in whom platinum‑based therapy is contraindicated. Administration of immunooncology drugs requires determination of PD-L1, for which various diagnostic systems are used. The question regarding correlation of results of determination of PD-L1 expression remains of concern.

Materials and Methods. The study was performed on 100 samples of surgical and biopsy samples of urothelial cancer. Two clones of 22C3 and SP142 with corresponding detection systems were used for the study. PD-L1 expression was assessed in tumor and immune cells.

Results. The study demonstrated a high correlation of negative PD-L1 tumor status determined using both diagnostic agents (92 % and 97 %) and low correlation of results of positive PD-L1 status (67 % and 43 %).

Conclusions. Thus, if a negative result of PD-L1 status of urothelial cancer is obtained using any of the diagnostic agents studied, repeated test with the other antibody is not required. If positive status is obtained in one test, the patient may have a negative status in the other test, which allows recommending a repeated testing in borderline cases using a test, recommended for the medicinal product untended for treatment.

1. Tsimafeyeu I, Tjulandin S. First line checkpoint inhibitors in PD-L1 positive patients with advanced urothelial carcinoma. BJU Int. 2018 Nov 20. doi: 10.1111/bju.14627. [Epub ahead of print].

2. Sonpavde G, Galsky MD, Latini D, Chen GJ. Cisplatin ineligible and chemotherapy ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clin Genitourin Cancer 2014; 12: 71–73.

3. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open label, phase 3 randomised controlled trial. Lancet. 2018 Feb 24;391 (10 122):748–757.

4. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first line treatment in cisplatin ineligible patients with locally advanced and metastatic urothelial carcinoma: a single arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7; 389 (10 064): 67–76.

5. Balar AV, Castellano D, O'Donnell PH, et al. First line pembrolizumab in cisplatin ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE 052): a multicentre, single arm, phase 2 study. Lancet Oncol. 2017 Nov; 18 (11): 1483–1492.

6. Vuky J, Balar AV, Castellano D, O'Donnell PH, et al. Updated efficacy and safety of KEYNOTE 052: A single arm phase 2 study investigating first line pembrolizumab (pembro) in cisplatin ineligible advanced urothelial cancer (UC). Journal of Clinical Oncology 36, no. 15_suppl (May 2018) 4524–4524. doi: 10.1200/JCO.2018.36.15_suppl.4524

7. Zavalishina L, Tsimafeyeu I, Povilaitite P, et al. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. Virchows Arch. 2018. https://doi.org/10.1007/s00428-018-2453-7.

8. Tretiakova M, Fulton R, Kocherginsky M, et al. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Mod Pathol. 2018 Apr;31 (4):623–632.

9. Burgess EF, Livasy C, Hartman A, et al. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol. 2019 Jan 16. pii: S1078–1439 (19) 30 002 X. doi: 10.1016/j.urolonc.2019.01.002. [Epub ahead of print].